ImmunoGen, Inc. — Operating Income by Fiscal Year
13 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/6986b3b2-7946-45b7-a0c0-f42137b2a925/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2022 | $-220.9M | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-002558 |
| FY 2021 | $-125.1M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-002358 |
| FY 2020 | $-22.4M | 2020-01-01 – 2020-12-31 | evidence 0001558370-21-002170 |
| FY 2019 | $-92.2M | 2019-01-01 – 2019-12-31 | evidence 0001558370-20-002399 |
| FY 2018 | $-161.4M | 2018-01-01 – 2018-12-31 | evidence 0001558370-19-001432 |
| FY 2017 | $-59.0M | 2017-01-01 – 2017-12-31 | evidence 0001558370-18-001641 |
| FY 2016 | $-135.6M | 2016-01-01 – 2016-12-31 | evidence 0001558370-18-001641 |
| FY 2015 | $-54.5M | 2014-07-01 – 2015-06-30 | evidence 0001047469-15-007008 |
| FY 2014 | $-71.5M | 2013-07-01 – 2014-06-30 | evidence 0001047469-14-007236 |
| FY 2013 | $-73.0M | 2012-07-01 – 2013-06-30 | evidence 0001047469-13-008741 |
| FY 2012 | $-73.3M | 2011-07-01 – 2012-06-30 | evidence 0001047469-12-008592 |
| FY 2011 | $-60.2M | 2010-07-01 – 2011-06-30 | evidence 0001047469-12-008592 |
| FY 2010 | $-51.2M | 2009-07-01 – 2010-06-30 | evidence 0001047469-12-008592 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).